ANI Pharmaceuticals (ANIP) vs uniQure N.V. (QURE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ANI Pharmaceuticals (ANIP) has outperformed uniQure N.V. (QURE) over the past year, losing 18.6% versus a loss of 64.5%. Over five years, ANIP leads with a +91.7% price change compared with -24.9% for QURE. ANI Pharmaceuticals is the larger company by market cap ($1.70 billion vs $1.57 billion), about 1.1 times the size.
ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIP | QURE |
|---|---|---|
| Share price | $73.89 | $22.59 |
| Market cap | $1.70B | $1.57B |
| 1-day change | +2.65% | +0.22% |
| YTD return | -6.40% | -5.60% |
| 1-year return | -18.61% | -64.51% |
| 5-year return | +91.72% | -24.85% |
| P/E ratio (TTM) | 15.99 | — |
| Forward P/E | 7.27 | — |
| EPS (TTM) | $4.62 | $-4.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $883.37M | $16.10M |
| Revenue growth (YoY) | +43.78% | -40.64% |
| Net income (latest FY) | $78.34M | $-198.97M |
| Gross margin | 61.36% | 89.53% |
| Operating margin | 12.58% | -1151.38% |
| Net margin | 8.87% | -1236.00% |
| 52-week high | $97.00 | $71.50 |
| 52-week low | $69.58 | $8.73 |
| Distance from 52-week high | -23.82% | -68.41% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.16% | +175.92% |
| Average volume | 376.38K | 1.97M |
| Shares outstanding | 22.96M | 69.37M |
| Employees | 970 | 221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIP has outperformed QURE by 45.9 percentage points over the past year.
- ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- ANI Pharmaceuticals grew revenue faster in its latest fiscal year (+43.78% vs -40.64%).
About ANI Pharmaceuticals
ANIP stock →ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.
Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
ANIP vs QURE FAQ
Which is bigger, ANI Pharmaceuticals or uniQure N.V.?
ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.70B compared with $1.57B for uniQure N.V. (QURE).
Which stock has performed better over the past year, ANIP or QURE?
ANIP returned -18.61% over the past 12 months, compared with -64.51% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are ANI Pharmaceuticals and uniQure N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.